Axsome Therapeutics, Inc. (AXSM) stock
AXSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$134.00−1.95 (-1.43%)
Close on Nov 18, 2026Market cap $7.02BP/E –Yield –
Axsome Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Axsome Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $187.86M, down 3.5% year over year. For fiscal 2025 it was $183.28M, down 2.0% from the year before. Over ten years it grew 39.1% a year on average. The highest annual figure on record is $187.08M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $183.28M | -2.0% |
| FY2024 | Dec 31, 2024 | $187.08M | +91.0% |
| FY2023 | Dec 31, 2023 | $97.94M | +69.0% |
| FY2022 | Dec 31, 2022 | $57.95M | -0.2% |
| FY2021 | Dec 31, 2021 | $58.06M | -17.3% |
| FY2020 | Dec 31, 2020 | $70.24M | +30.9% |
| FY2019 | Dec 31, 2019 | $53.65M | +128.3% |
| FY2018 | Dec 31, 2018 | $23.50M | +17.7% |
| FY2017 | Dec 31, 2017 | $19.96M | -5.9% |
| FY2016 | Dec 31, 2016 | $21.20M | +212.8% |
| FY2015 | Dec 31, 2015 | $6.78M | +58.4% |
| FY2014 | Dec 31, 2014 | $4.28M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $46.23M | -6.7% |
| Q1 FY2026 | Mar 31, 2026 | $52.68M | +17.6% |
| Q4 FY2025 | Dec 31, 2025 | $48.79M | -11.3% |
| Q3 FY2025 | Sep 30, 2025 | $40.16M | -11.5% |
| Q2 FY2025 | Jun 30, 2025 | $49.54M | -0.6% |
| Q1 FY2025 | Mar 31, 2025 | $44.79M | +21.6% |
| Q4 FY2024 | Dec 31, 2024 | $55.01M | +78.6% |
| Q3 FY2024 | Sep 30, 2024 | $45.39M | +57.8% |
| Q2 FY2024 | Jun 30, 2024 | $49.85M | +142.2% |
| Q1 FY2024 | Mar 31, 2024 | $36.83M | +107.0% |
| Q4 FY2023 | Dec 31, 2023 | $30.80M | +109.6% |
| Q3 FY2023 | Sep 30, 2023 | $28.77M | +93.4% |
| Q2 FY2023 | Jun 30, 2023 | $20.58M | +30.3% |
| Q1 FY2023 | Mar 31, 2023 | $17.79M | +41.4% |
| Q4 FY2022 | Dec 31, 2022 | $14.69M | +6.6% |
| Q3 FY2022 | Sep 30, 2022 | $14.88M | +12.9% |
| Q2 FY2022 | Jun 30, 2022 | $15.79M | +8.9% |
| Q1 FY2022 | Mar 31, 2022 | $12.59M | -24.2% |
| Q4 FY2021 | Dec 31, 2021 | $13.78M | -20.7% |
| Q3 FY2021 | Sep 30, 2021 | $13.18M | -10.9% |
| Q2 FY2021 | Jun 30, 2021 | $14.50M | +37.6% |
| Q1 FY2021 | Mar 31, 2021 | $16.60M | -39.7% |
| Q4 FY2020 | Dec 31, 2020 | $17.38M | -9.5% |
| Q3 FY2020 | Sep 30, 2020 | $14.80M | -6.6% |
| Q2 FY2020 | Jun 30, 2020 | $10.54M | -4.2% |
| Q1 FY2020 | Mar 31, 2020 | $27.52M | +262.0% |
| Q4 FY2019 | Dec 31, 2019 | $19.21M | +168.6% |
| Q3 FY2019 | Sep 30, 2019 | $15.84M | +162.1% |
| Q2 FY2019 | Jun 30, 2019 | $11.00M | +98.2% |
| Q1 FY2019 | Mar 31, 2019 | $7.60M | +60.0% |
| Q4 FY2018 | Dec 31, 2018 | $7.15M | +59.1% |
| Q3 FY2018 | Sep 30, 2018 | $6.04M | +35.1% |
| Q2 FY2018 | Jun 30, 2018 | $5.55M | +10.8% |
| Q1 FY2018 | Mar 31, 2018 | $4.75M | -20.6% |
| Q4 FY2017 | Dec 31, 2017 | $4.49M | -22.6% |
| Q3 FY2017 | Sep 30, 2017 | $4.47M | -19.7% |
| Q2 FY2017 | Jun 30, 2017 | $5.01M | – |
| Q1 FY2017 | Mar 31, 2017 | $5.99M | – |
| Q4 FY2016 | Dec 31, 2016 | $5.81M | – |
| Q3 FY2016 | Sep 30, 2016 | $5.57M | – |
See a number that looks wrong?